학술논문
Comparative Clinical Study of Ofloxacin and Cefaclor in Bacterial Bronchitis / 気管支炎に対するOfloxacin (DL-8280) とCefaclorの薬効比較試験成績
Document Type
Journal Article
Author
Akira IKEBE; Akira ITO; Akira SAITO; Asako YAMAMOTO; Atsushi SAITO; Fukuo IIJIMA; Fumio MATSUMOTO; Fumio MIKI; Fusanosuke YAMASAKU; Fuyuhiko HIGASHI; Haruhiko TOKUOMI; Harumi SHISHIDO; Harushige KANNO; Hideo IKEMOTO; Hiroichi TANIMOTO; Hiroshi UCHIDA; Hirotada IKEDA; Hirotaka TAKIZAWA; Hiroyoshi ISHIBASHI; Hiroyuki KOBAYASHI; Hisao KIMURA; Ichiro NAKAYAMA; Ippei FUJIMORI; Isao NITTA; Izumi HAYASHI; Jiro HINO; Jun GOTO; Jun TAMAOKI; Junzaburo KABE; Kaneo SUZUKI; Kaoru OKADA; Kaoru OYAMA; Katsuhiro OKAMOTO; Katsumasa TOKUNAGA; Katsutaka TORIKAI; Kazuaki HANAOKA; Kazufuto FUKAYA; Kazukiyo OIDA; Kazuo TAKEBE; Kazuyoshi WATANABE; Keiichi NAGAO; Keiichi NAKAGAWA; Keimei MASHIMO; Keizo MATSUMOTO; Keizo YAMAGUCHI; Kenji TAKAMATSU; Kenji TAKAMURA; Kenji TSUCHIHASHI; Kentaro WATANABE; Kohei AOKI; Kohei HARA; Kohki KIKUCHI; Kohya SHIBA; Koichiro NAKATA; Kota KONO; Kou MUROHASHI; Kunihiko SHINDO; Kunihiko YOSHIMURA; Kunihiro ISHITANI; Kyoko WATANABE; Makoto ISHIZAKI; Masako KATO; Masamoto NAKANO; Masanobu KAJI; Masanori ADACHI; Masao TAMURA; Masaru KOYAMA; Masaru NASU; Masashi YONEDA; Masataka KATSU; Masatoshi WATANABE; Masayasu KAWANISHI; Masayuki ANDO; Masumi TOMIZAWA; Michiyasu NAKANISHI; Mikio OKA; Mineharu SUGIMOTO; Mitsuo NAKAMURA; Mitsuo OBANA; Moritaka SUGA; Naohiko CHONABAYASHI; Naoto RIKITOMI; Nobuki AOKI; Nobuo MAEKAWA; Noriko MURAKI; Norio KIKUCHI; Osamu KURIMURA; Osamu SEKINE; Rinzo SOEJIMA; Ruey-Mei CHEN; Ryuo NAKATANI; Shigeki ODAGIRI; Shigeru OCHIAI; Shinichi INADA; Shohei WATANABE; Shuichi TAKAHASHI; Shuichiro YOSHIDA; Tadashi MIYAHARA; Takao TAKIZAWA; Takashi ITO; Takashi ITOGA; Takashi KAMO; Takehisa YAMAJI; Takekuni IWATA; Takeshi KAWAI; Takeshi MITSUI; Tamotsu KANEKO; Tatsuro IRIE; Tatsuya ABE; Teruo AOYAGI; Tomio ONUMA; Tsuneo HAMAMOTO; Tsunetoshi KOTEDA; Yasutoshi SUZUKI; Yasutsugu FUKUDA; Yasuyuki SANO; Yoichi ABE; Yoji SUZUYAMA; Yomei HIRAGA; Yoshiaki FUKUDA; Yoshihiko ARATANI; Yoshihiro KUMAZAKA; Yoshiji YAMANE; Yoshimaru USUDA; Yoshio KOBAYASHI; Yoshio TAGUCHI; Yoshiro SAWAE; Yoshitaka NAKAMORI; Yoshiteru SHIGENO; Yoshito NIKI; Yuichi KOIZUMI; Yukio KUMAGAI; Yuzo FUNATSU; 三井 健司; 三木 文雄; 中山 一朗; 中川 圭一; 中村 光男; 中森 祥隆; 中田 紘一郎; 中西 通泰; 中谷 龍王; 中野 正心; 二木 芳人; 伊藤 章; 伊藤 隆司; 佐野 靖之; 入江 達朗; 内田 博; 前川 暢夫; 副島 林造; 力富 直人; 加地 正伸; 加茂 隆; 加藤 真砂子; 勝 正孝; 原 耕平; 可部 順三郎; 吉村 邦彦; 吉田 秀一郎; 土橋 賢治; 大山 馨; 安藤 正幸; 安達 正則; 安部 陽一; 宍戸 春美; 室橋 光宇; 宮原 正; 富沢 磨須美; 小山 優; 小林 宏行; 小林 芳夫; 小沼 富男; 小泉 雄一; 小田切 繁樹; 小花 光夫; 山作 房之輔; 山口 恵三; 山本 朝子; 山根 至二; 山路 武久; 岡 三喜男; 岡本 勝博; 岡田 薫; 岩田 猛邦; 川西 正泰; 平賀 洋明; 後藤 純; 徳永 勝正; 徳臣 晴比古; 斉藤 厚; 斎藤 玲; 斎藤 篤; 新田 功; 日野 二郎; 木村 久男; 杉本 峯晴; 村木 憲子; 東 冬彦; 松本 慶蔵; 松本 文夫; 林 泉; 柴 孝也; 栗村 統; 武部 和夫; 池本 秀雄; 池田 大忠; 池辺 璋; 沢江 義郎; 河合 健; 河野 浩太; 浜本 恒男; 深谷 一太; 渡辺 一功; 渡辺 京子; 渡辺 健太郎; 渡辺 昌平; 渡辺 正俊; 滝沢 敬夫; 瀧澤 弘隆; 熊坂 義裕; 熊谷 幸雄; 玉置 淳; 田口 善夫; 田村 昌士; 真下 啓明; 石崎 騎; 石橋 弘義; 石谷 城宏; 福田 安嗣; 福田 義昭; 種田 和清; 稲田 進一; 籠手田 恒敏; 米田 政志; 糸賀 敬; 船津 雄三; 花岡 和明; 荒谷 義彦; 菅 守隆; 菅野 治重; 菊地 弘毅; 菊池 典雄; 落合 滋; 薄田 芳丸; 藤森 一平; 蝶名林 直彦; 谷本 普一; 進藤 邦彦; 那須 勝; 重野 芳輝; 金子 保; 鈴山 洋司; 鈴木 周雄; 鈴木 康稔; 長尾 啓一; 関根 理; 阿部 達也; 陳 瑞明; 青木 信樹; 青木 幸平; 青柳 昭雄; 飯島 福生; 高村 研二; 高松 健次; 高橋 修一; 鳥飼 勝隆
Source
感染症学雑誌 / Kansenshogaku Zasshi. 1984, 58(9):832
Subject
Language
Japanese
ISSN
0387-5911
1884-569X
1884-569X
Abstract
The clinical efficacy and safety of ofloxacin (OFLX; DL-8280) and cefaclor (CCL) were compared bya double-blind study using 250 patients with bacterial bronchitis. Patients were orally administered witheither 200 mg of OFLX or 250 mg of CCL three times a day for 14 days, and the following results wereobtained.1) Clinical efficacy judged by committee:The efficacy rate of acute bronchitis was 86.7% in OFLX group and 85.7% in CCL group. On theother hand, 78.4% of the patients in OFLX group and 50.0% of those in CCL group were effective inchronic bronchitis group. Statistically significant difference was observed between OFLX group andCCL group in chronic bronchitis group (p°0.001).2) Clinical efficacy judged by the doctors in charge:The results of the clinical efficacy judged by the doctors in charge was similar to the efficacy judgedby committee.3) Bacteriological efficacy judged by committee:Eradication rate of OFLX group was 90.2%(55 of 61 strains) and that of CCL group was 50%(35 of70 strains) (p°0.001). Furthermore, H influenzae and K pneumoniae were eliminated in a higher rate inOFLX group than in CCL group (p°0.001, p°0.05, respectively).4) Side effects and abnormal laboratory findings:Side effects were observed in 10 cases (8.1%) in OFLX group and in 10 cases (8.4%) in CCL group.Both OFLX and CCL did not show serious side effects or abnormal laboratory findings. There was nosignificant difference bwtween the two drug groups in the incidence of side effects and abnormallaboratory findings.5) Clinical utility:When the clinical utility was expressed by the satisfaction rate (very satisfied and satisfied), it was75.7% in OFLX group (107 patients) and 52.7% in CCL group (110 patients) (judged by committee).When the utility was judged by doctors in charge, it was 68.9% in OFLX group and 43.0% in CCL group.Both results revealed that OFLX was significantly superior to CCL (p°0.001).From these results, it was confirmed that OFLX was a more useful drug than CCL for the treatmentof bacterial bronchitis.